11.15.06
Bristol-Myers Squibb Co. has promoted Andrew Bonfield, chief financial officer, and Elliott Sigal, M.D., Ph.D., chief scientific officer, to executive vice presidents of the company. They join Lamberto Andreotti, president, worldwide pharmaceuticals. Mr. Andreotti leads global pharmaceuticals operations, as well as technical operations and global marketing at the company.
Mr. Bonfield will continue to lead global finance and strategic planning and issues management. Dr. Sigal continues his leadership of the Pharmaceutical Research Institute (PRI), the R&D arm of the company.
"Andrew and Elliott have played critical roles in the execution of the corporate strategy," said James M. Cornelius, chief executive officer, BMS. "Andrew has delivered superior oversight of the company's financial and operating performance, and was instrumental in integrating compliance throughout the company with new requirements under the Sarbanes-Oxley Act. Under Elliott's leadership, the PRI has delivered eight new product approvals in fewer than four years. This is outstanding performance by any measure."
Mr. Bonfield previously served as director of finance at the BG Group, PLC, an international energy company. Prior to that, he was chief financial officer at SmithKline Beecham -- now GlaxoSmithKline -- responsible for all aspects of the company's finances, including corporate control, operations, finance, tax, strategy and development.
Dr. Sigal has held senior positions in both discovery and development in the PRI, joining the company nearly 10 years ago to start its genomics department. As chief scientific officer, he achieved five new product approvals: Orencia, Sprycel, Baraclude, Emsam and Atripla. As senior vice president of clinical development, he secured the approvals of Abilify, Erbitux and Reyataz.
Mr. Bonfield will continue to lead global finance and strategic planning and issues management. Dr. Sigal continues his leadership of the Pharmaceutical Research Institute (PRI), the R&D arm of the company.
"Andrew and Elliott have played critical roles in the execution of the corporate strategy," said James M. Cornelius, chief executive officer, BMS. "Andrew has delivered superior oversight of the company's financial and operating performance, and was instrumental in integrating compliance throughout the company with new requirements under the Sarbanes-Oxley Act. Under Elliott's leadership, the PRI has delivered eight new product approvals in fewer than four years. This is outstanding performance by any measure."
Mr. Bonfield previously served as director of finance at the BG Group, PLC, an international energy company. Prior to that, he was chief financial officer at SmithKline Beecham -- now GlaxoSmithKline -- responsible for all aspects of the company's finances, including corporate control, operations, finance, tax, strategy and development.
Dr. Sigal has held senior positions in both discovery and development in the PRI, joining the company nearly 10 years ago to start its genomics department. As chief scientific officer, he achieved five new product approvals: Orencia, Sprycel, Baraclude, Emsam and Atripla. As senior vice president of clinical development, he secured the approvals of Abilify, Erbitux and Reyataz.